Menu Search
Equities

TYK Medicines Inc

2410:HKG

TYK Medicines Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)24.40
  • Today's Change0.000 / 0.00%
  • Shares traded49.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year TYK Medicines Inc's revenues fell -100.00% from 44.24m to 0.00. has fallen 22.97% from a loss of 310.99m to a larger loss of 382.43m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in CNYView more

In 2023, TYK Medicines Inc increased its cash reserves by 105.85%, or 96.07m. Cash Flow from Financing totalled 224.00m or -- of revenues. In addition the company used 200.94m for operations while cash from investing totalled 73.01m.
Cash flow per share-1.17
Price/Cash flow per share--
Book value per share-3.06
Tangible book value per share-3.25
More ▼

Balance sheet in CNYView more

TYK Medicines Inc uses little or no debt in its capital structure.
Current ratio0.1407
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.